



15 April 2026

## CHANGE OF DIRECTOR'S INTEREST NOTICE AND FINAL DIRECTOR'S INTEREST NOTICE FOR DR GISELA MAUTNER

Noxopharm Limited (ASX: NOX) (the **Company**) attaches the following ASX releases in respect of the resignation of Dr Gisela Mautner as Managing Director and CEO on 14 April 2026, as announced to the ASX on 14 April 2026:

- (i) Final Director's Interest Notice ("Appendix 3Z"); and
- (ii) Change of Director's Interest Notice ("Appendix 3Y").

### Appendix 3Y

The Appendix 3Y covers the lapsing of unlisted options, which occurred on 6 November 2024. The lapsing of the options was announced to the ASX through the lodgement of an Appendix 3H on 6 November 2024, however due to an administrative oversight, the Appendix 3Y was not announced.

NOX maintains a Continuous Disclosure Policy and Securities Trading Policy and is in regular communication with its directors. The Company and Directors are aware of NOX's obligations under the Listing Rules, including Listing Rule 3.19A.

The Company Secretary prepares the Appendix 3Y, liaises with the relevant director to ensure the information provided is accurate and then lodges the Appendix 3Y on the ASX Market Announcements Platform. These actions must occur within 5 business days of the date of change of the director's interests.

In this instance, due to an administrative oversight, this was not completed. While NOX's current arrangements to ensure compliance with Listing Rule 3.19B are adequate and are being enforced, NOX has taken further precautions to ensure this omission doesn't occur again, including for the Company to prepare regular reconciliations between the registry records, financial records and ASX releases.

### Appendix 3Z

Although not under a contract, and therefore not able to be disclosed in the Appendix 3Z, the Company notes the following for completeness, being securities that may be issued in the future.

Shareholders approved on 19 November 2024 (being Resolution 4 of the NOX 2024 Annual General Meeting (**AGM**)) the issue of 350,000 Loan Funded Shares at a market price of \$0.071 per Loan Funded Share, being the closing share price on 31 December 2023. Full details of these securities are as outlined in the Notice of Meeting of the AGM.

The securities are yet to be issued, however have been approved by shareholders at the AGM to be issued in the name of Dr Gisela Mautner or her nominee. The approval received allows the securities to be issued up to 3 years from the AGM.

Other than as outlined above, Dr Mautner did not hold any other securities in NOX at the time of her resignation as detailed in the attached Appendix 3Z.

**-ENDS-**

## About Noxopharm

Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a wide range of mRNA medicines. The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Sofra™ (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma™ (oncology).

To learn more, please visit: [noxopharm.com](http://noxopharm.com)

**Investor, Corporate & Media enquiries:**

Julian Elliott

M: 0425 840 071

E: [julian.elliott@noxopharm.com](mailto:julian.elliott@noxopharm.com)

**Company Secretary:**

David Franks

T: +61 2 8072 1400

E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

*Mr Fred Bart, Chair of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.*

---

## Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward looking statement.

# Appendix 3Z

## Final Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	Noxopharm Limited
<b>ABN</b>	50 608 966 123

We (the entity) give ASX the following information under listing rule 3.19.A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	Gisela Mautner
<b>Date of last notice</b>	15 April 2026
<b>Date that director ceased to be director</b>	14 April 2026

### Part 1 - Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b>
Nil

### Part 2 - Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

<b>Name of holder &amp; nature of interest</b> <i>Note: Provide details of the circumstances giving rise to the relevant interest.</i>	<b>Number &amp; class of Securities</b>
Nil	Nil

### Part 3 - Director's interests in contracts

<b>Detail of contract</b>	N/A - however please refer to cover release dated 15 April 2026
<b>Nature of interest</b>	N/A - however please refer to cover release dated 15 April 2026

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Z**  
**Final Director's Interest Notice**

---

<b>Name of registered holder (if issued securities)</b>	N/A - however please refer to cover release dated 15 April 2026
<b>No. and class of securities to which interest relates</b>	N/A - however please refer to cover release dated 15 April 2026

For personal use only

---

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Noxopharm Limited
<b>ABN</b>	50 608 966 123

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	Gisela Mautner
<b>Date of last notice</b>	18 December 2023

### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	1) Direct
<b>Nature of indirect interest (including registered holder)</b>	N/A
<b>Date of change</b>	1) 06 November 2024
<b>No. of securities held prior to change</b>	1) 135,000 - UNLISTED OPTIONS @ \$0.55 EXP 6/11/2024
<b>Class</b>	1) UNLISTED OPTIONS @ \$0.55 EXP 6/11/2024
<b>Number acquired</b>	1) N/A
<b>Number disposed</b>	1) (135,000) - UNLISTED OPTIONS @ \$0.55 EXP 6/11/2024
<b>Value/Consideration</b>	1) N/A
<b>No. of securities held after change</b>	1) NIL - UNLISTED OPTIONS @ \$0.55 EXP 6/11/2024
<b>Nature of change</b>	1) OPTIONS LAPSED AS PER THE APPENDIX 3H RELEASED TO THE ASX ON 6 NOVEMBER 2024  <a href="https://stocknessmonster.com/news/nox.asx/2024/">https://stocknessmonster.com/news/nox.asx/2024/</a>

### Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A

<sup>+</sup> See [chapter 19](#) for defined terms.

Date of change	N/A
No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

**Part 3 - <sup>+</sup>Closed period**

Were the interests in the securities or contracts detailed above traded during a <sup>+</sup> closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

For personal use only